Tumor DNA in Yttrium-90-exposed tissue

Tumor DNA in Yttrium-90 (Y90)-exposed tissue refers to the genomic material within cancerous cells that has been subjected to internal radiation therapy, typically via transarterial radioembolization (TARE). Y90 is a high-energy beta-emitting isotope that delivers localized radiation to tumor-associated vasculature and parenchyma, leading to extensive molecular alterations in the tumor's deoxyribonucleic acid (Salem et al., 2019, Journal of Vascular and Interventional Radiology). The primary biological impact involves the induction of lethal DNA double-strand breaks and oxidative stress, which triggers apoptotic pathways and tumor necrosis (Kennedy et al., 2004, International Journal of Radiation Oncology, Biology, Physics). In clinical research, this DNA is analyzed to evaluate treatment efficacy, monitor clonal evolution, and identify biomarkers of resistance or response. While not a therapeutic target in the traditional sense of a drug-binding protein, it serves as the primary substrate for the cytotoxic effects of radiotherapy and a critical source of diagnostic information in oncology (Dhanasekaran et al., 2019, Nature Reviews Gastroenterology & Hepatology). Understanding the state of tumor DNA after Y90 exposure is crucial for determining the efficacy of the radiation and for planning subsequent lines of therapy, such as immunotherapy or systemic chemotherapy.

Other names

Y90-irradiated tumor DNAPost-radioembolization tumor DNAPost-TARE tumor DNARadiation-damaged tumor DNA

Induction of DNA double-strand breaks and oxidative stress via localized beta radiation.